The selling pressure seen by Arena Pharmaceuticals (ARNA -16.4%) remains intense, as shares give...
Friday, June 22, 2012, 12:25 PM ETThe selling pressure seen by Arena Pharmaceuticals (ARNA -16.4%) remains intense, as shares give back a healthy chunk of their recent gains. Possibly hurting Arena's cause is an article from SA's Shane Blackmon, who notes Arena's rally has been fueled by short-covering (22% of the float was shorted as of May 31), and argues "a bear raid seems inevitable" ahead of the FDA's expected June 27 decision on the company's Locaserin weight-loss drug.
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles